Cargando…

RET Inhibitors in Non-Small-Cell Lung Cancer

SIMPLE SUMMARY: Non-small cell lung cancer (NSCLC) remains a significant cause of death worldwide, despite the significant progresses to date. Multiple molecular alterations have been identified in NSCLC, leading to the development of target-based agents that have shown significant clinical benefits...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cascetta, Priscilla, Sforza, Vincenzo, Manzo, Anna, Carillio, Guido, Palumbo, Giuliano, Esposito, Giovanna, Montanino, Agnese, Costanzo, Raffaele, Sandomenico, Claudia, De Cecio, Rossella, Piccirillo, Maria Carmela, La Manna, Carmine, Totaro, Giuseppe, Muto, Paolo, Picone, Carmine, Bianco, Roberto, Normanno, Nicola, Morabito, Alessandro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8431193/ https://www.ncbi.nlm.nih.gov/pubmed/34503226 http://dx.doi.org/10.3390/cancers13174415

Ejemplares similares

Lurbinectedin in small cell lung cancer
por: Manzo, Anna, et al.
Publicado: (2022)

Immunotherapy in Small Cell Lung Cancer
por: Esposito, Giovanna, et al.
Publicado: (2020)

Angiogenesis and epidermal growth factor receptor inhibitors in non-small cell lung cancer
por: Palumbo, Giuliano, et al.
Publicado: (2020)

Angiogenesis Inhibitors in Small Cell Lung Cancer
por: Montanino, Agnese, et al.
Publicado: (2021)

BRAF Inhibitors in Non-Small Cell Lung Cancer
por: Sforza, Vincenzo, et al.
Publicado: (2022)

Angiogenesis Inhibitors in NSCLC
por: Manzo, Anna, et al.
Publicado: (2017)

Liquid Biopsy Testing for the Management of Patient with Non-Small Cell Lung Cancer Carrying a Rare Exon-20 EGFR Insertion
por: Morabito, Alessandro, et al.
Publicado: (2022)

Surgery in Small-Cell Lung Cancer
por: Martucci, Nicola, et al.
Publicado: (2021)

Focus on Nintedanib in NSCLC and Other Tumors
por: Manzo, Anna, et al.
Publicado: (2016)

Gefitinib in Non Small Cell Lung Cancer
por: Costanzo, Raffaele, et al.
Publicado: (2011)

KRAS in NSCLC: State of the Art and Future Perspectives
por: Cascetta, Priscilla, et al.
Publicado: (2022)

The Presence of Concomitant Mutations Affects the Activity of EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Patients
por: Rachiglio, Anna Maria, et al.
Publicado: (2019)

Next Generation Sequencing-Based Profiling of Cell Free DNA in Patients with Advanced Non-Small Cell Lung Cancer: Advantages and Pitfalls
por: Esposito Abate, Riziero, et al.
Publicado: (2020)

Immunotherapy Assessment: A New Paradigm for Radiologists
por: Granata, Vincenza, et al.
Publicado: (2023)

Pancreatic Cancer and Obesity: Molecular Mechanisms of Cell Transformation and Chemoresistance
por: Cascetta, Priscilla, et al.
Publicado: (2018)

Multiple endocrine neoplasias type 2B and RET proto-oncogene
por: Martucciello, Giuseppe, et al.
Publicado: (2012)

Combining Immune Checkpoint Inhibitors with Anti-Angiogenic Agents
por: Ciciola, Paola, et al.
Publicado: (2020)

Multiple sclerosis - New treatment modalities
por: Totaro, Rocco, et al.
Publicado: (2015)

Precision therapy for RET-altered cancers with RET inhibitors
por: Thein, Kyaw Z., et al.
Publicado: (2021)

RET kinase inhibitors for RET-altered thyroid cancers
por: Vodopivec, Danica M., et al.
Publicado: (2022)

RET signaling pathway and RET inhibitors in human cancer
por: Regua, Angelina T., et al.
Publicado: (2022)

Higher RET Gene Expression Levels Do Not Represent anAlternative RET Activation Mechanism in Medullary Thyroid Carcinoma
por: Mulè, Chiara, et al.
Publicado: (2021)

RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies
por: Solomon, Benjamin J., et al.
Publicado: (2020)

Imaging Assessment of Interval Metastasis from Melanoma
por: Simonetti, Igino, et al.
Publicado: (2022)

Twenty-Five Years Experience on RET Genetic Screening on Hereditary MTC: An Update on The Prevalence of Germline RET Mutations
por: Elisei, Rossella, et al.
Publicado: (2019)

Ret-dependent and Ret-independent mechanisms of Gfl-induced sensitization
por: Schmutzler, Brian S, et al.
Publicado: (2011)

Selective RET kinase inhibition for patients with RET-altered cancers
por: Subbiah, V, et al.
Publicado: (2018)

RET/PTC Translocations and Clinico-Pathological Features in Human Papillary Thyroid Carcinoma
por: Romei, Cristina, et al.
Publicado: (2012)

RET Copy Number Alteration in Medullary Thyroid Cancer Is a Rare Event Correlated with RET Somatic Mutations and High Allelic Frequency
por: Ramone, Teresa, et al.
Publicado: (2020)

Hallmarks of RET and Co-occuring Genomic Alterations in RET-aberrant Cancers
por: Adashek, Jacob J., et al.
Publicado: (2021)

The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers
por: Rosen, Ezra Y., et al.
Publicado: (2022)

Precision oncology with selective RET inhibitor selpercatinib in RET-rearranged cancers
por: Gouda, Mohamed A., et al.
Publicado: (2023)

Involvement of RET oncogene in human tumours: specificity of RET activation to thyroid tumours.
por: Santoro, M., et al.
Publicado: (1993)

Response to RET-Specific Therapy in RET Fusion-Positive Anaplastic Thyroid Carcinoma
por: Dias-Santagata, Dora, et al.
Publicado: (2020)

The RET gene encodes RET protein, which triggers intracellular signaling pathways for enteric neurogenesis, and RET mutation results in Hirschsprung's disease
por: Bhattarai, Chacchu, et al.
Publicado: (2022)

Quantitative imaging decision support (QIDS(TM)) tool consistency evaluation and radiomic analysis by means of 594 metrics in lung carcinoma on chest CT scan
por: Fusco, Roberta, et al.
Publicado: (2021)

miRNA Profiling Reveals Dysregulation of RET and RET-Regulating Pathways in Hirschsprung's Disease
por: Li, Shuangshuang, et al.
Publicado: (2016)

EGF Induced RET Inhibitor Resistance in CCDC6-RET Lung Cancer Cells
por: Chang, Hyun, et al.
Publicado: (2017)

Aggravated pulmonary injury after subarachnoid hemorrhage in PDGF-B(ret/ret) mice
por: Pan, Pengyu, et al.
Publicado: (2020)

Author Correction: The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers
por: Rosen, Ezra Y., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_uhlqitvhb68rdiv60rs75de0q4